GlassScriptPhysician profile
Monica Dhar
NPI 1083630255
$767.88
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $68.09 · 2021: $105 · 2022: $118.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $247.37 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $174.05 | 2019 | |
| Amgen INC. | $124.99 | 2019 | |
| Insmed, INC. | $104.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.32 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.54 | 2022 | |
| Circassia INC. | $14.87 | 2019 | |
| Horizon Therapeutics Plc | $14.66 | 2022 | |
| Tris Pharma INC | $14.62 | 2020 | |
| Vertical Pharmaceuticals, LLC | $10.96 | 2019 | |
| Pfizer INC. | $10.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Dhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.